| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | Zinc finger protein 589, Stem cell zinc finger protein 1, ZNF589, SZF1 |
| Entrez GeneID | 51385 |
| WB Predicted band size | 41.2kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This ZNF589 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 184-210 amino acids from the Central region of human ZNF589. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CD267(TNFRSF13B/TACI)抗体的3篇代表性文献的简要总结(注：文献信息为模拟示例，仅供参考)：
---
1. **文献名称**: *"Targeting TACI in autoimmune diseases: therapeutic potential of anti-CD267 antibodies"*
**作者**: Zhang L, et al.
**摘要**: 研究探讨了抗CD267单克隆抗体在系统性红斑狼疮(SLE)模型中的作用，发现其通过抑制B细胞过度活化和自身抗体产生，显著减轻肾脏炎症和疾病进展。
---
2. **文献名称**: *"A novel anti-CD267 antibody enhances apoptosis in multiple myeloma cells"*
**作者**: Rossi JF, et al.
**摘要**: 开发了一种靶向CD267的人源化抗体，体外实验表明其可诱导多发性骨髓瘤细胞凋亡，并与蛋白酶体抑制剂协同增强抗肿瘤效果，提示其作为联合疗法的潜力。
---
3. **文献名称**: *"CD267 antibody-based flow cytometry for diagnosing common variable immunodeficiency"*
**作者**: Tangye SG, et al.
**摘要**: 建立了一种基于抗CD267抗体的流式细胞术检测方法，用于评估常见变异型免疫缺陷病(CVID)患者的B细胞功能异常，提高了诊断准确性和分型效率。
---
**备注**：实际文献需通过PubMed或Google Scholar等平台检索关键词(如CD267 antibody, TACI therapeutic, TNFRSF13B)，建议优先选择近5年内的研究以反映最新进展。
**Background of CD267 Antibody**
CD267. also known as transmembrane activator and CAML interactor (TACI) or TNFRSF13B, is a cell-surface receptor belonging to the tumor necrosis factor receptor superfamily. Primarily expressed on B lymphocytes and plasma cells, TACI plays a critical role in regulating B-cell activation, survival, and antibody production. It binds to two ligands: a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), which are essential for humoral immune responses.
CD267 antibodies are tools or therapeutics designed to target this receptor. Research has linked TACI dysfunction to immune disorders, such as common variable immunodeficiency (CVID), systemic lupus erythematosus (SLE), and multiple myeloma. For instance, mutations in *TNFRSF13B* (encoding TACI) may impair B-cell signaling, leading to hypogammaglobulinemia or autoantibody production. Conversely, overactivation of TACI/BAFF/APRIL pathways is associated with B-cell malignancies and autoimmune diseases.
Therapeutically, anti-CD267 antibodies (e.g., telitacicept) aim to modulate these pathways. By blocking TACI-ligand interactions, they can suppress excessive B-cell activity, offering potential treatments for autoimmune conditions or B-cell-related cancers. CD267 antibodies also serve as research reagents to study B-cell biology, receptor-ligand dynamics, and disease mechanisms. Their dual role in diagnostics and therapy highlights their significance in immunology and translational medicine.
×
